Hematología

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Cutaneous Lymphoma Database

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

2. A Study to Evaluate Performance of Coagulation Laboratory Testing in Children and Young Adults

   Rochester, Minn.

   The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies.

3. Extracorporeal Photopheresis And Mogamulizumab For The Treatment Of Erythrodermic Cutaneous T Cell Lymphoma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma.  

4. A Dose-Escalation And Expansion Study Of BGB-16673 In Participants With B-Cell Malignancies

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

5. In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells

   Rochester, Minn.

   This study will establish  in vivo and ex vivo methodologies of assessing the utilization of extracellular nutrients by normal bone marrow plasma cells from healthy subjects.

6. A Study to Determine the Effects of Activity by Ambulation in Hospital Premises versus Strict Protective Isolation on Quality of Life in Severely Neutropenic Cancer Patients during Hospitalization

   Jacksonville, Fla.

   The purpose of this study is to determine if allowing patients to ambulate in the hallways outside of their hospital room by relaxing the policy of strict protective isolation in neutropenic patients improves the quality of life, and if this increases the risk of infection among these patients during hospitalization.

7. A Study to Collect Data and Blood Samples from Mayo Patients Who Have or are Suspected of Having Amyloidosis, or Their Family Members, for Future Research

   Rochester, Minn.

   The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

8. MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

   Mankato, Minn., Rochester, Minn., Jacksonville, Fla., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis., Albert Lea, Minn.

   The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

9. A Study Of ABBV-383 With Relapsed Refractory Waldenström Macroglobulinemia

   Rochester, Minn.

   The purpose of this study is to determine the safety, maximum tolerated dose (MTD) and RP2D of ABBV-383 monotherapy for patients with RRWM and to determine VGPR or deeper response as the best response achieved with ABBV 383 within 12 cycles  of initiation of therapy for patients with RRWM.

10. CD19-Directed CAR-T Cell Therapy For The Treatment Of Relapsed/​Refractory B Cell Malignancies

    Rochester, Minn.

    The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients.

    The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood. In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer. The new modified T cells are called the IC19/1563 treatment. The dose of IC19/1563 will depend on when the patient is enrolled on to the study.